

INVESTOR FACT SHEET



Business Summary

Novogen is a drug development company focused on bringing into the clinic novel therapeutics for degenerative diseases, cancer in particular.

The Company has two proprietary drug technology platforms, each targeting novel drug targets within the cell: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs).

SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the cytoskeleton of the cancer cell and when used in conjunction with standard anti-cytoskeleton drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton.

Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to both first-line therapy and salvage therapy.

Oncology Pipeline

There are 4 lead candidate drugs. All currently are pre-clinical but scheduled to enter the clinic between 3Q15-2Q16:

Cantrixil – an SBP drug product developed as an intra-cavity chemotherapy for the treatment of cancers involving the peritoneal and pleural cavities. Cantrixil is owned by CanTx Inc, a joint venture company between Novogen and Yale University. Malignant ascites is the primary clinical indication.

TRXE-009 – an SBP drug that has high potency against cancers of cells deriving from the neural crest. Brain cancers and melanoma in adults, and brain cancers and neuroblastoma in children are the primary clinical indications.

ASX code	NRT
NASDAQ code	NVGN
Share price (7/1/15)	13.5 cents
Number of shares	~246.59m
Market capitalisation	~\$33.29m
52 week range	27/8cents

TRXE-0025 – an SBP drug with high potency against prostate cancer. The primary clinical indication is castrate-resistant prostate cancer.

Anisina – an ATM drug candidate to be used to synergize taxanes and vinca alkaloids in melanoma, prostate cancer and neuroblastoma.

History

Established 1994. Listed Australian Securities Exchange (ASX) 1994 and NASDAQ 1997.

Board of Directors

Dr Graham Kelly—Chairman and CEO
John O'Connor—Non Executive Director
Steven Coffey—Non Executive Director
Prof Peter Gunning—Non Executive Director

Auditors

Grant Thornton Audit Pty Ltd
Level 17, 383 Kent Street
SYDNEY NSW 2000

Share Registry

Computershare Investor Services Pty Ltd
Level 4
60 Carrington St
SYDNEY NSW 2000

Australia

16-18 Edgeworth David Ave
HORNSBY NSW 2077,
Australia
+61 2 9472 4100


United States

5 Science Park
New Haven

Corporate Contact
CEO & Chairmam
Dr Graham Kelly
Graham.Kelly@novogen.com
+61 2 9472 4100

Media Enquiries
Chief Operating Officer
Cristyn Humphreys
Cristyn.Humphreys@novogen.com
+61 2 9472 4111

Novogen timeline



Legend

TTPL	Triaxial Pharmaceuticals Pty Ltd
SBPs	Super- benzopyrans
ATM	Anti—tropomyosins
CanTx	CanTx Inc is a joint venture between Novogen and Yale University